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Abstract: 
Aim: As part of an on going investigation of novel anticancer agents from natural origin, the 
biological and cellular effects of (5Z)-7-oxozeaenol on cancer cells were investigated. Materials 
and Methods: The expression of nuclear factor kappa B (NF-κB), IκB kinase (IKKα), IKKβ and 
caspase-3 were analyzed by western blot. Reactive oxygen species (ROS) fluorescence and 
caspase luminescent assays were used to assess the intracellular effects in HeLa cervical and HT-
29 colon cancer cell lines. The mitochondrial transmembrane potential (MTP) was analyzed by 
fluorescence-activated cell sorting (FACS). Results: Cells treated with (5Z)-7-oxozeaenol 
exhibited down-regulation of NF-κB in a dose-dependent manner. Treatment with (5Z)-7-
oxozeaenol significantly enhanced the levels of ROS in HeLa and HT-29 cells. MTP was 
reduced in HT-29 cells. The expression of caspase-3 and -7 was induced in (5Z)-7-oxozeaenol 
treated HeLa cells, in comparison with those treated with paclitaxel. Conclusion: Our findings 
suggest that (5Z)-7-oxozeaenol is a potent inhibitor of the NF-κB pathway and potentiates the 
production of ROS, as well as induces caspase-3 and -7 in HeLa and HT-29 cancer cells. Thus, 
(5Z)-7-oxozeaenol represents a new lead compound for drug development, particularly as a new 
cancer chemotherapeutic agent, since programmed cell death might be mediated through the 
activation of a caspase-arbitrated pathway. 
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Abstract. Aim: As part of an on going investigation of
novel anticancer agents from natural origin, the biological
and cellular effects of (5Z)-7-oxozeaenol on cancer cells
were investigated. Materials and Methods: The expression of
nuclear factor kappa B (NF-κB), IκB kinase (IKKα), IKKβ
and caspase-3 were analyzed by western blot. Reactive
oxygen species (ROS) fluorescence and caspase luminescent
assays were used to assess the intracellular effects in HeLa
cervical and HT-29 colon cancer cell lines. The
mitochondrial transmembrane potential (MTP) was analyzed
by fluorescence-activated cell sorting (FACS). Results: Cells
treated with (5Z)-7-oxozeaenol exhibited down-regulation of
NF-κB in a dose-dependent manner. Treatment with (5Z)-7-
oxozeaenol significantly enhanced the levels of ROS in HeLa
and HT-29 cells. MTP was reduced in HT-29 cells. The
expression of caspase-3 and -7 was induced in (5Z)-7-
oxozeaenol treated HeLa cells, in comparison with those
treated with paclitaxel. Conclusion: Our findings suggest
that (5Z)-7-oxozeaenol is a potent inhibitor of the NF-κB
pathway and potentiates the production of ROS, as well as
induces caspase-3 and -7 in HeLa and HT-29 cancer cells.
Thus, (5Z)-7-oxozeaenol represents a new lead compound for
drug development, particularly as a new cancer
chemotherapeutic agent, since programmed cell death might
be mediated through the activation of a caspase-arbitrated
pathway.
The transcription factor NF-κB is a heterodimer composed
of subunits p50 and p65(1). IκB kinase (IKKβ) and NF-κB
are induced in response to extracellular inflammatory stimuli
e.g. by proinflammatory cytokinins (IL-1), tumor necrosis
factor-α (TNF-α), and epidermal growth factors (EGF) (2).
When inactive, NF-κB is found sequestered in the cytoplasm,
bound to subunit inhibitor of kappa-B (IκB). After
phosphorylation of IκB by IKK, NF-κB is subsequently
released and translocated to the nucleus, where it exerts its
effects, activating a wide range of target genes that are
involved in apoptosis inhibition, cell adhesion, and cell
mediation. Induction of NF-κB prevents cancer cells from
entering apoptosis (3). As a result, cancer cells are induced to
survive instead of undergoing apoptosis. Thirty-five out of
the 60 NF-κB-related genes are up-regulated in inflammatory
breast cancer (4), which are related to apoptosis, immune
response, proliferation, tumor promotion and angiogenesis.
The activation of the NF-κB cell signaling pathway is
responsible for survival, proliferative control, and, moreover,
it promotes the resistance to certain tumorigenic agents and
chemotherapy (4). 
In this study, the effects of the resorcylic acid lactone,
(5Z)-7-oxozeaenol (Figure 1), on the oxidative pathway of
cervical (HeLa) and colonic (HT-29) cancer cells, were
examined. (5Z)-7-Oxozeaenol was previously isolated from a
filamentous fungus (5) and was reported by our group as an
NF-κB inhibitor. It has previously been shown by the
Matsumoto research group that (5Z)-7-oxozeaenol inhibits
transforming growth factor β-activated kinase 1 (TAK1), a
member of the mitogen-activated kinase (MAPK) family,
likely by competitively binding at the ATP-binding site.
Moreover, the inhibition of TAK1 resulted in decreased
IKKβ activity(6). The data presented herein indicate that
(5Z)-7-oxozeaenol inhibits the NF-κB survival pathway (7,
8), interfering with TNFα signaling, and possibly through
targeting and inhibition of TAK1 (9). The expression of NF-
κB p65, p50, IKKα, IKKβ and caspase-3 were studied by
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western blot analysis in HeLa cells. The production of
intracellular ROS and the mitochondrial membrane potential
were also evaluated using HT-29 cells. 
Secondary metabolites of natural origin, such as (5Z)-7-
oxozeaenol, represent new lead compounds in drug
development, particularly as new cancer chemotherapeutic
agents (10). For example, a closely related analog of (5Z)-7-
oxozeaenol, termed E6201, is in phase II clinical trials by
Eisai Inc. for the treatment of melanoma (11, 12), as well as
being a possible topical agent for treatment of psoriasis (13).
Materials and Methods
Compound source. (5Z)-7-Oxozeaenol was isolated from a
filamentous fungus by our research group, as part of the drug
discovery program (5). Vitamin C, iron sulphate (FeSO4) and
hydrogen peroxide (H2O2) were purchased from Sigma Aldrich (St.
Louis, MO, USA). Rocaglamide was obtained from Enzo Life
Sciences, Inc (Farmingdale, NY, USA).
Cell culture. Colonic cancer HT-29 and cervical cancer HeLa cell lines
were obtained from the American Type Culture Collection, Manassas,
VA, USA. HT-29 cells were cultured in RPMI 1640 medium
supplemented with 10% fetal bovine calf serum (FBS) (Gibco,
Rockville, MD, USA) and 10% antibiotic-antimycotic. HeLa cells
were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% fetal bovine calf serum and 10% antibiotic-
antimycotic from Gibco. Cells were kept at 37˚C, in an atmosphere
with 5% CO2. 
Immunoblotting. To observe the effects of (5Z)-7-oxozeaenol on the
NF-κB pathway, HeLa cells were treated over a range of
concentrations (0.008, 0.016, 0.4, 2.0 and 10 μM) for 24 h. Briefly,
cells were then lysed using PhosphoSafe Lysis Buffer (Novagen,
Madison, WI, USA). Protein concentration in the lysates was
determined by using the Bradford protein assay kit and the albumin
standard (Thermo Scientific, Rockford, IL, USA). Optical density
of protein solutions from the cell extracts and of the serial dilutions
from the albumin standard were measured at 562 nm, using Fluostar
Optima plate reader (BMG Labtech Inc, Durham, NC, USA).
Lysates were analyzed by western blot. Equal amounts of protein
(20 μg) were loaded together with lithium dodecyl sulphate (LDS)
sample loading buffer (Invitrogen, Carlsbad, CA, USA) and
resolved using Nu-PAGE 10% sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) Bis-Tris gels,
together with SeeBlue® Plus2 Pre-Stained Standard Ladder
(Invitrogen). Electrophoresis was performed using SDS-PAGE
running buffer in a Nu-PAGE XCell SureLock Module from
Invitrogen. Proteins were transferred from the gel to a
polyvinyldiene fluoride (PVDF) membrane using tris buffered saline
with tween-20 buffer (TBS-T). The blots were then blocked at room
temperature using non-fat milk and subsequently probed using
primary antibodies (1:1000) against each target protein using 1%
bovine serum albumine (BSA) in TBS-T overnight. Primary
antibodies (caspase-3, NF-κB p65 (65kDa), p50 (50kDa), IKKα and
IKKβ) were purchased from Cell Signaling Technologies (Beverly,
MA, USA). The secondary, horseradish peroxidase (HRP)
conjugated antibodies (1:2000) were obtained from Santa Cruz
Biotechnology Inc, (Santa Cruz, CA, USA). Conjugated antibodies
were detected using Chemiluminescent substrates Supersignal
Femto LumiGLO kit from Thermo Scientific. 
Mitochondrial transmembrane potential (ΨΔm) assay. The
Mitochondria Transmembrane Potential (MTP) fluorescence-activated
cell sorting (FACS) assay kit (Cayman Chemical Company, Ann
Arbor, MI, USA) was used to assess the MTP (ΨΔm) in colon cancer
cells, after treatment using FACS analysis (14). The cells were seeded
on 10-cm plates and treated with (5Z)-7-oxozeaenol for 24 h. After
this time, the cells were harvested using Trypsin-EDTA (Gibco),
washed in phosphate-buffered saline (PBS) and re-suspended in assay
buffer. The potentiometric dye 5,5’,6,6’-tetrachloro-1,1’,3,3’-
tetraethylbenzimidazoylcarbocyanine iodide (JC-1) was used to stain
the HT-29 cells. A volume of 50 μl of JC-1 stain was added to the
cells, followed by incubation for 15 min at 37˚C in 5% CO2. At high
ΨΔm, red fluorescent J-aggregates are formed in healthy cells;
however, in apoptotic cells with low ΨΔm, JC-1 remains in the
monomeric form, which only exhibits green fluorescence. Analysis
was performed using FACS Canto II (BD Biosciences, San Jose, CA,
USA). The mitochondrial function was assessed, and J-aggregates
were detected using an excitation wavelength of 520-570 nm, and
emission of 570-610 nm, respectively.
ROS assay. The assay was performed following a previously
described procedure (15). The fluorescent probe 2’,7’-
dichlorfluorescein-diacetate (DCFH-DA) was used to detect the
presence of ROS in (5Z)-7-oxozeaenol treated cells, in the absence
and in the presence of H2O2. Cells were seeded in 96-well plates and
treated with (5z)-7-oxozeaenol (0.28 μM-280 μM) or the controls,
followed by a 5 h incubation before treated with H2O2 (1.25 mM)
and FeSO4 (0.2 mM) for 30 min. Vitamin C (0.28 μM-280 μM) and
H2O2 were used as controls. The fluorescent probe DCFH-DA was
added to detect intracellular ROS. Fluorescence was detected and
measured using FLUOstar Optima fluorescence plate reader (BMG
Labtechnologies GmbH, Inc., Durham, NC, USA), with an excitation
wavelength of 485 nm and on emission wavelength of 530 nm. All
treatments were performed in triplicate and the data shown are
representative of at least two different experiments. 
Caspase-3/7 assay. Caspase-3 and 7 activities were measured using
the Caspase–Glo3/7® assay from Promega, Madison, WI, USA.
HeLa cells were treated with different concentrations of (5Z)-7-
oxozeaenol (0.08-10 μM) for 3 h. Paclitaxel (0.0001-1 μM) was
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Figure 1. Chemical structure of (5Z)-7-oxozeaenol (5).
used as a positive control. Caspase–Glo3/7® reagent was then added
and luminescence was recorded using Fluostar Optima plate reader
(BMG Labtechnologies GmbH, Inc., Durham, NC, USA) at 37˚C
and the enzymatic activity was calculated. Each data point is an
average of triplicate readings from two separate experiments.
Results
Immunoblotting. In a previous report, our natural product
drug discovery program identified (5Z)-7-oxozeaenol (0.25
μM) (Figure 1) as being an NF-κB inhibitor in comparison
with the positive control rocaglamide (0.075 μM) (5). In
this study, NF-κB inhibition induced by (5Z)-7-oxozeaenol
was further confirmed by western blot analysis. The
inhibitory effects of (5Z)-7-oxozeaenol on mediators of the
NF-κB pathway, and more specifically the attenuating
effect on NF-κB p65 and p50, was found to be
concentration-dependent (Figure 2). Similarly, the
expression of IKKβ, an up-stream mediator in the pathway,
was found to be down-regulated in a concentration-
dependent manner in treated cells (Figure 3). 
MTP FACS assay. (5Z)-7-Oxozeaenol was also reported by our
group previously, as having a moderate effect on the
mitochondrial membrane potential after treatment for a period
of 3 h. This effect was further examined here after treating HT-
29 cells for 24 h, by using JC-1 staining to assess the ΨΔm.
Treated HT-29 cells had fewer JC-1 aggregates than the
untreated cells (Figure 4). 
Munoz Acuna et al: Effects of (5Z)-7-Oxozeaenol on Cancer Cells
2667
Figure 2. Western blot analysis performed on HeLa cellular extracts showed that (5Z)-7-oxozeaenol suppresses NF-κB p65 and p50 activation. A
decrease in activity was detected upon treatment with higher concentrations of (5Z)-7-oxozeaenol. 
Figure 3. Expression of IκB kinase alpha (IKKα) and IKKβ was down-regulated in treated HeLa cells. β-Actin was used as an internal control to
establish equivalent loading.
ROS assay. The ROS assay was performed in the absence
and the presence of H2O2/FeSO4 in HeLa and HT-29 cells
(Figures 5 and 6), respectively. H2O2 and Vitamin C were
used as controls. The intracellular levels of ROS increased
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Figure 4. JC-1 aggregates in untreated HT-29 cells detected at a
wavelength of 564-606 nm (A). JC-1 monomers detected on treated cells
(B). Mitochondrial transmembrane potential (ΔΨm) assay showed J-
aggregates detected at 564-606 nm in untreated, non-apoptotic HT-29
cells (in gray), and apoptotic HT-29 cells after 24-h treatment with (5Z)-
7-oxozeaenol (in black) (C).
Figure 5. Reactive oxygen species (ROS) evaluation of (5Z)-7-
oxozeaenol using HeLa cells in the absence (A) and presence (B) of
hydrogen peroxide (H2O2). In this assay, H2O2 and vitamin C were used
as positive and negative controls, respectively. Cells were treated at four
different concentration levels (0.28 μM-280 μM) for 5 h. ROS was
detected with fluorescent probe 2’,7’-dichlorfluorescein-diacetate
(DCFH-DA) at 485 nm emission wavelength and 530 nm excitation
wavelength. Each experiment was carried out in triplicate and the graph
represents the results of two separate experiments. Values in (A) and (B)
represent the means of fluorescence units (FU) ± SEM of triplicate
samples from two independent experiments.
in a concentration-dependent manner when cells were treated
with (5Z)-7-oxozeaenol in the absence of H2O2. (5Z)-7-
Oxozeaenol was also tested in combination with H2O2 to
evaluate its potentiating effect in increasing ROS levels.
Noticeable, (5Z)-7-oxozeaenol induced significantly the
elevation of intracellular ROS in the absence and in the
presence of H2O2.
Caspase-3/7 assays. Caspase-3/7 enzyme activity was
induced after 3 h of treatment with different concentrations
of (5Z)-7-oxozeaenol in HeLa cells (Figure 7). Western blot
analysis further confirmed that caspase-3 activity was
induced in a dose dependent manner, when treating HeLa
cells with (5Z)-7-oxozeaenol (Figure 8). 
Discussion
Oxidative stress plays an important role in cellular status and
oxygen-derived species such as superoxide radical, hydrogen
peroxide, singlet oxygen and hydroxyl radical are well known
for being cytotoxic and have been implicated in the etiology of
a wide array of human diseases, including cancer. The
dynamic state of cellular ROS depends on the equilibrium
between the internal generation of ROS and the cell’s
antioxidant system. The NF-κB pathway is generally thought
to be a primary oxidative stress-response pathway, since nearly
all pathways leading to NF-κB activation are blocked by a
variety of antioxidative agents. Cancer cells in particular, in
comparison to normal cells, have higher levels of ROS and are
more susceptible to mitochondrial dysfunction due to their
higher metabolic rate, making the oxidative pathway an
attractive target for cancer drug discovery. 
In this study, it was hypothesized that (5Z)-7-oxozeaenol is
an NF-κB inhibitor that acts specifically on the TNFα-mediated
pathway. The results of the present study show that even
though (5Z)-7-oxozeaenol treatment did not inhibit K-Ras
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Figure 6. Reactive oxygen species (ROS) evaluation in HT-29 cells
treated with (5Z)-7-oxozeaenol in the absence (A) and presence (B) of
peroxide (H2O2). The cells were treated at four different concentrations
(0.28 μM-280 μM) for 5 h. ROS were detected with fluorescent probe
2’,7’-dichlorfluorescein-diacetate (DCFH-DA) at 485 nm emission
wavelength and 530 nm excitation wavelength. In this assay, H2O2 and
vitamin C were used as positive and negative controls, respectively. Each
experiment was carried out in triplicate and the graph represents the
results of two separate experiments. Values in (A) and (B) represent the
means of fluorescence units (FU) ± SEM of triplicate samples from two
independent experiments.
Figure 7. Caspase-3/7 activity after 3 h of treatment with (5Z)-7-
oxozeaenol. Positive control was paclitaxel. Bars on graph represent the
means of relative luminescence units (RLU) ± SEM of triplicate samples
from two independent experiments.
activity, induced by epidermal growth factor (EGF) (figure data
not shown, but (5Z)-7-oxozeaenol exhibited less than 50%
inhibition at 125 μM), it acts as an inhibitor of the TNFα-
mediated NF-κB pathway. When HeLa cells were treated with
(5Z)-7-oxozeaenol in the presence of TNFα, both NF-κB p65
and p50 were inhibited in a dose-dependent manner. The
expression of IKKβ was also dose-dependently down
regulated. Consequently, NF-κB was not activated, remaining
in the cytoplasm in its inactive form, potentially inhibiting
tumor survival signaling in treated cancer cells. (5Z)-7-
Oxozeaenol also induced the production of ROS, both in the
absence and in the presence of H2O2, in a dose-dependent
manner, as shown in Figures 5 and 6. Inducing elevation of
ROS levels in cancer cells might be a selective approach to
preferentially kill cancer cells through pharmacological ROS
insults, since cancer cells are already under high oxidative
stress. This suggests that (5Z)-7-oxozeaenol might also affect
mitochondrial function and that apoptosis may be induced
through a caspase-dependent pathway. In the present study,
increased intracellular levels of ROS were followed by loss of
mitochondrial function, as well as cell death, as an effect of
(5Z)-7-oxozeaenol treatment of HT-29 cells. 
According to previous reports, there is a direct correlation
between TNFα stimulation and mitochondrial ROS production
that triggers TNFα-mediated apoptosis (16). The results of this
investigation show that (5Z)-7-oxozeaenol inhibits TNFα-
induced NF-κB activity in HeLa and HT-29 cells, thereby
affecting the functions of mitochondria. There is increasing
evidence (16, 17) suggesting that constitutively expressed NF-
κB plays a fundamental role in the regulation of oxidative
metabolism, and is moreover a vital physiological regulator of
mitochondrial respiration in cancer cells. Previous work
showed that NF-κB is involved in oncogenic transformation
and cellular reprogramming for the metabolic adaptation
required by cancer cells (17). Subsequently, (5Z)-7-oxozeaenol
treatment might also lead to ROS-mediated cell death.
Furthermore, IKKβ and NF-κB inhibition makes tumors highly
susceptible to mitochondrial stress, both in vitro and in vivo
(17). It has been shown that IKKβ inhibition sensitizes
leukemia cells to starvation-induced cell death (16). In
agreement with previous findings, this study shows that (5Z)-7-
oxozeaenol inhibits IKKβ/NF-κB by targeting upstream
signaling mediators. It is possible this inhibition would affect
the ubiquitination of the NF-κB complex and subsequent
proteasome degradation of the transcription element. Our
results showed that the mitochondrial transmembrane potential
and function were affected in treated HT-29 cells and increased
production of ROS was also detected in a dose-dependent
manner, likely promoting cell death. NF-κB inhibitory agents,
such as (5Z)-7-oxozeaenol, which down-regulate and suppress
the NF-κB survival pathway and induce cell death by ROS
accumulation and activation of caspase-3 activity, are potential
new anti-tumorigenic lead compounds (9). Analogs of (5Z)-7-
oxozeaenol used in combination with other anticancer agents
may increase the efficacy of existing treatments, possibly acting
synergistically with chemotherapeutic agents. 
Conclusion
In conclusion, these findings suggest that (5Z)-7-oxozeaenol
prevents the activation of NF-κB, compromising the
mitochondria membrane potential, and increasing the level
of intracellular ROS in HeLa and HT-29 cells, leading to
programmed cell death through the activation of a caspase-
mediated pathway.
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